| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530403000 | Protein is identified as an antigen, e.g., immunogenic carriers, etc. | 15 |
| 20090118475 | Clostridial Neurotoxin Compositions and Modified Clostridial Neurotoxins - Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In some embodiments, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular ailments and pain. | 05-07-2009 |
| 20100280229 | POLYPEPTIDE - The present invention provides a polypeptide inducing the production of an antibody in permucosal administration in the presence of no immunological adjuvant, a composition containing the polypeptide, and use thereof. The present invention solves the above object by providing a polypeptide inserted with a cell attachment motif of a cell adhesive molecule to the peptide which has an amino acid sequence of multiagretope type T cell epitope at the amino terminal side of an inserted linker peptide, and an amino acid sequence of a B cell epitope at the carboxyl terminal side of the inserted linker peptide, a composition containing the polypeptide, and use thereof. | 11-04-2010 |
| 20110015376 | Papilloma Virus-Like Particles, Fusion Proteins as Well as Processes for Their Production - The invention relates to the recombinant production of proteins as well as VLPs which are suitable as a vaccine for therapeutic and prophylactic vaccination. The invention also relates to processes for the production and purification of recombinant papilloma virus proteins and fusion proteins. | 01-20-2011 |
| 20110201791 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 08-18-2011 |
| 20120283421 | METHODS AND REAGENTS FOR DECREASING CLINICAL REACTION TO ALLERGY - It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino acid within the protein, preferably a hydrophobic residue towards the center of the IgE epitope, to eliminate IgE binding. Additionally or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemically, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE epitopes and disrupting one or more disulfide bonds of the natural allergen. In certain embodiments, the methods of the present invention allow allergens to be modified while retaining the ability of the protein to activate T-cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The Examples provided herein use peanut allergens to illustrate applications of the invention. | 11-08-2012 |
| 20130317205 | Conformationally Specific Viral Immunogens - The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine. | 11-28-2013 |
| 20140221628 | INFLUENZA VIRUS-LIKE PARTICLES COMPRISING ADJUVANT-FUSED M2 PROTEIN TO ENHANCE THE IMMUNOGENICITY OF VACCINE - A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided. A method for eliciting an immune response against a plurality of avian influenza virus subtypes in a subject, comprising delivering the DNA vaccine or the DNA vaccine composition to tissue of the subject is also provided | 08-07-2014 |
| 20160168194 | CHROMATOGRAPHY MATRICES INCLUDING NOVEL STAPHYLOCOCCUS AUREUS PROTEIN A BASED LIGANDS | 06-16-2016 |
| 530404000 | Sulfur containing reactant | 1 |
| 20120029175 | Protein Complex and Process for Producing the Same - A process for producing an embedded protein antigen, comprising embedding a protein antigen having two or more cysteine residues in a molecule thereof, into a hydrophobized polysaccharid. Prior to or after the embedding of the protein antigen, the protein antigen is purified. There are provided an embedded protein antigen and a process for producing the same, which can advantageously purify the protein antigen, while suppressing the denaturation of the protein antigen as completely as possible. | 02-02-2012 |
| 530405000 | Nitrogen containing reactant | 4 |
| 20100204458 | Process for the Production of Immunogenic Compositions - The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3. | 08-12-2010 |
| 20110257377 | Covalently linked complexes of HIV TAT and ENV PROTEINS - Complexes of HIV Env and Tat proteins are advantageous as immunogens compared to Tat or Env alone, but they may dissociate when combined with a vaccine adjuvant. To avoid dissociation, complexes of Env and Tat are stabilized by the use of covalent cross linking. The extent of cross linking is important to the binding properties of the complexes, and so is controlled to avoid the loss of Env's ability to bind specifically to CD4 and Tat's ability to bind specifically to anti-Tat monoclonal antibodies. | 10-20-2011 |
| 20120259101 | Isopeptide Bond Formation in Bacillus Species and Uses Thereof - A mechanism for a unique isopeptide bond formation between polypeptides is disclosed as well as sequence motifs used in such bond formation and methods of using such sequence motifs. | 10-11-2012 |
| 20130245241 | Risperidone Immunoassay - Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids. | 09-19-2013 |
| 530406000 | Oxygen containing reactant | 2 |
| 20100130731 | CRYSTAL STRUCTURE OF P53 MUTANTS AND THEIR USE - The invention relates to crystals of p53 which have mutations in the β-sandwich region at positions 220, 143 or 270. The structures may be used for computer-based drug design to identify ligands which can bind within the β-sandwich region in order to stabilize the proteins. | 05-27-2010 |
| 20130172538 | METHOD FOR PRODUCING POROUS PARTICLES, POROUS PARTICLES, ADSORBENT BODY, AND METHOD FOR PURIFYING PROTEIN - The objective of the present invention is to provide a method for easily producing a porous cellulose particle which can be used as an adsorbent for various substances in a safe manner without using a highly toxic solvent such as a calcium thiocyanate solution. In addition, the objective of the present invention is to provide a porous particle produced by the production method, an adsorbent which contains the porous particle and by which a highly pure protein can be efficiently purified in a safe manner, and a method for purifying a protein by using the adsorbent. The method for producing a porous particle according to the present invention is characterized in comprising the steps of preparing a solution containing cellulose and an ionic liquid; preparing a dispersion by dispersing the obtained cellulose solution into a liquid, wherein the liquid is not compatible with the ionic liquid; and coagulating the dispersion by bringing into contact with an alcohol or an alcohol aqueous solution in order in order to obtain the porous particle. | 07-04-2013 |
